RxDoctor Payments DataLook up a doctor →

Jennifer Goldberg, PA

Physician Assistant · Montclair, NJNPI 1235149774

Payments from drug & device makers

$15,666in general payments, 2019–2025

Across 1,079 payments — averaging $14.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$2K
  • AbbVie$2K
  • Amgen$1K
  • Incyte Corporation$1K
  • Lilly USA, LLC$907
  • LEO Pharma Inc.$882
  • plus $8K from 28 others

What the payments were for

  • Consulting fees$5003%
  • Speaking & faculty fees$9006%
  • Food & beverage$13,67487%
  • Education$5924%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,666 in reported general payments places this provider in the 95th percentile of 2,726 physician assistant providers in New Jersey.

See all physician assistant providers in New Jersey

Medicare billing

Part B allowed, 2024
$138,122
Medicare patients
460
Services billed
2,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Taltz AutoinjectorIxekizumab19$138,048
SotyktuDeucravacitinib13$84,580
Humira PenAdalimumab12$81,244
Clobetasol Propionate55$3,602
Ketoconazole65$1,391
Fluocinolone AcetonideFluocinolone/Shower Cap18$1,345
Tacrolimus11$1,043
Dutasteride26$982
Doxycycline Hyclate56$762
Triamcinolone Acetonide45$718
Hydrocortisone48$515
Fluocinonide19$471
Minoxidil46$418
ValacyclovirValacyclovir Hcl19$325
Mupirocin43$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Sotyktu$863$84,58013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,726 physician assistant providers in New Jersey.

Other physician assistant in Montclair

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →